28. The formulation of any one of claims 18 to 27, wherein the solvent is present in an amount of about 1 wt% to about 99.94 wt%.

29. The formulation of any one of claims 1 to 28, wherein the formulation is suitable for oral administration.

30. The formulation of any one of claims 1 to 28, wherein the formulation is suitable for parenteral administration.

31. The formulation of any one of claims 1 to 30 which is a veterinary or a human pharmaceutical formulation.

32. The formulation of claim 31 which is a veterinary formulation.

33. The formulation of any one of claims 1 to 32, wherein the formulation is diluted with water.

34. Use of a formulation of any one of claims 1 to 33 in the manufacture of a medicament for treating cardiac disease and/or hypertension in a subject in need thereof.

35. The use according to claim 34, wherein cardiac disease is a primary heart disease selected from the group consisting of congestive heart failure (CHF), acute CHF, chronic CHF, decompensated endocardiosis (DCE), dilated cardiomyopathy (DCM), asymptomatic (occult) CHF, asymptomatic DCM, and chronic valvular heart disease, or a combination thereof.

36. The use according to claim 34, wherein cardiac disease is a secondary heart disease and is selected from the group consisting of cardiovascular dysfunction and impaired renal perfusion during anaesthesia, shock, gastric dilation, volvulus, myocardial ischaemia, and renal ischaemia, or a combination thereof.

37. The use according to any one of claims 34 to 36, wherein the subject is a companion animal.

38. The use according to claim 37, wherein the subject is a dog or a cat.

39. The use according to any one of claims 34 to 38, wherein the medicament is to be administered via oral administration.

40. The use according to any one of claims 34 to 38, wherein the medicament is to be administered via parenteral administration.

28. The formulation of any one of claims 18 to 27, wherein the solvent is present in an amount of about 1 wt% to about 99.94 wt%.

29. The formulation of any one of claims 1 to 28, wherein the formulation is suitable for oral administration.

30. The formulation of any one of claims 1 to 28, wherein the formulation is suitable for parenteral administration.

31. The formulation of any one of claims 1 to 30 which is a veterinary or a human pharmaceutical formulation.

32. The formulation of claim 31 which is a veterinary formulation.

33. The formulation of any one of claims 1 to 32, wherein the formulation is diluted with water.

34. A method of treating cardiac disease and/or hypertension, comprising administering the liquid formulation of any one of claims 1 to 33 to a subject in need thereof.

35. The method of claim 34, wherein cardiac disease is a primary heart disease selected from the group consisting of congestive heart failure (CHF), acute CHF, chronic CHF, decompensated endocardiosis (DCE), dilated cardiomyopathy (DCM), asymptomatic (occult) CHF, asymptomatic DCM, and chronic valvular heart disease, or a combination thereof.

36. The method of claim 34, wherein cardiac disease is a secondary heart disease is selected from the group consisting of cardiovascular dysfunction and impaired renal perfusion during anaesthesia, shock, gastric dilation, volvulus, myocardial ischaemia, and renal ischaemia, or a combination thereof.

37. The method of any one of claims 34 to 36, wherein the subject is a companion animal.

38. The method of claim 37, wherein the subject is a dog or a cat.

39. The method of any one of claims 34 to 38, wherein the administration is oral administration.

40. The method of any one of claims 34 to 38, wherein the administration is parenteral administration.